SLS SELLAS Life Sciences Group, Inc. - Common Stock
SELLAS Life Sciences Group, Inc. - Common Stock について Wikipediaからの企業概要
Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..
続きを読む
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigation their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗
SLS 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ
SLS 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ
10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド
バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か？
収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC
財務健全性 負債、流動性、支払能力 — バランスシートの健全性
成長 収益、EPS、純利益の成長率：前年比、3年CAGR、5年CAGR
資本効率 総資産回転率、棚卸資産回転率、売掛金回転率
SLS アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド
- 強い買い 1 16.7%
- 買い 4 66.7%
- 保有 1 16.7%
- 売り 0 0.0%
- 強い売り 0 0.0%
12ヶ月目標株価
2 アナリスト · 2026-08-14決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日
| 期間 | EPS Actual | EPS 予想 | サプライズ |
|---|---|---|---|
| 2026年3月31日 | $-0.05 | $-0.04 | -0.01% |
| 2025年12月31日 | $-0.05 | $-0.07 | 0.02% |
| 2025年9月30日 | $-0.06 | $-0.07 | 0.01% |
| 2025年6月30日 | $-0.07 | $-0.08 | 0.01% |
| 2025年3月31日 | $-0.07 | $-0.11 | 0.04% |
| 2024年12月31日 | $-0.08 | $-0.11 | 0.03% |
同業他社比較（GICSサブインダストリー） 主要メトリクスとセクターピアの比較
| ティッカー | 時価総額 | P/E | 売上高 YoY | 純利益率 | ROE | 粗利益率 |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| COAG | — | — | — | — | — | — |
| KLRA | — | — | — | — | — | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー
損益計算書 15
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
貸借対照表 22
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
キャッシュフロー 17
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
収益性 7
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
流動性と支払能力 4
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
効率性 1
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
成長率 1
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
バリュエーション（TTM） 17
| 指標 | トレンド | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
損益計算書 12
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | -185,663,932 | 108,396,260 | 98,558,567 | 87,760,320 | -109,495,111 | 68,254,021 | 57,630,506 | 44,812,996 | -52,473,798 | 28,355,427 | 28,347,920 | 23,547,562 | -37,350,745 | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
貸借対照表 15
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
キャッシュフロー 7
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
収益性 5
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
流動性と支払能力 2
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
効率性 1
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
バリュエーション（TTM） 9
| 指標 | トレンド | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $1M | · | $1M | |
| Net Income TTM | $-31M | $-28M | · | $-26M | $-27M | $-30M | · | $-33M | $-35M | $-39M | · | $-36M | $-35M | $-43M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -64.2 | -16.9 | · | -5.4 | -5.9 | -2.1 | · | -1.6 | -1.2 | -0.8 | · | -1.1 | -1.0 | -0.6 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 40.5 | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.6% | -5.9% | · | -18.6% | -16.9% | -47.2% | · | -61.6% | -82.3% | -130.7% | · | -88.4% | -97.5% | -158.7% | · | -111.4% |
財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間
損益計算書
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 収益 | — | — | $0 | $1M | $8M |
| 営業利益率 % | — | — | — | -4195.0% | -332.8% |
| 純利益 | $-27M | $-31M | $-37M | $-41M | $-21M |
| 希薄化後EPS | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
貸借対照表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流動比率 | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| クイックレシオ | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
最新ニュース この会社に言及した最近の見出し
マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行
あなたにとって重要なメトリクスを選択 — 上記の決算詳細の任意の行の横にある➕をクリックしてください。
選択内容は保存され、すべてのティッカーで引き継がれます。
機関投資家（13F） 231 提出者 · $1.2B合計 · 時点 2026年6月30日
四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。
| 新規ポジション | 解消済みポジション | 増加 | 減少 | 純株式数増減 |
|---|---|---|---|---|
| 87 (+24 前期比) | 19 (+4 前期比) | 70 (+12 前期比) | 38 (+15 前期比) | +39.9M |
Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。
| 機関投資家 | 評価額 | 株式数 | % 追跡された13Fのうち | タイプ |
|---|---|---|---|---|
| STATE STREET CORP | $191,829,196 | 12,996,558 | 15.97% | 株式数 |
| VANGUARD CAPITAL MANAGEMENT LLC | $121,417,310 | 8,226,105 | 10.11% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105,640,272 | 7,157,200 | 8.79% | コールオプション |
| Anson Funds Management LP | $66,420,000 | 4,500,000 | 5.53% | 株式数 |
| CITADEL ADVISORS LLC | $64,157,292 | 4,346,700 | 5.34% | コールオプション |
| GEODE CAPITAL MANAGEMENT, LLC | $61,905,400 | 4,193,009 | 5.15% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61,832,592 | 4,189,200 | 5.15% | プットオプション |
| CITADEL ADVISORS LLC | $33,333,984 | 2,258,400 | 2.77% | プットオプション |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31,897,821 | 2,161,099 | 2.66% | 株式数 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30,266,812 | 2,050,597 | 2.52% | 株式数 |
| JONES FINANCIAL COMPANIES LLLP | $28,553,511 | 2,304,561 | 2.38% | 株式数 |
| VANGUARD GROUP INC | $27,868,421 | 7,392,154 | 2.32% | 株式数 |
| Anson Funds Management LP | $27,245,484 | 1,845,900 | 2.27% | プットオプション |
| PERCEPTIVE ADVISORS LLC | $22,140,000 | 1,500,000 | 1.84% | プットオプション |
| VANGUARD FIDUCIARY TRUST CO | $19,707,050 | 1,335,166 | 1.64% | 株式数 |
| Sio Capital Management, LLC | $18,165,132 | 1,230,700 | 1.51% | プットオプション |
| BNP PARIBAS FINANCIAL MARKETS | $15,823,045 | 1,072,022 | 1.32% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $13,372,560 | 906,000 | 1.11% | プットオプション |
| BARCLAYS PLC | $11,831,616 | 801,600 | 0.98% | プットオプション |
| Anson Funds Management LP | $11,808,000 | 800,000 | 0.98% | コールオプション |
| BNP PARIBAS FINANCIAL MARKETS | $11,734,200 | 7,950 | 0.98% | プットオプション |
| JANE STREET GROUP, LLC | $11,058,192 | 749,200 | 0.92% | コールオプション |
| MORGAN STANLEY | $9,922,380 | 672,248 | 0.83% | 株式数 |
| BANK OF AMERICA CORP /DE/ | $9,150,359 | 619,943 | 0.76% | 株式数 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8,339,518 | 565,008 | 0.69% | 株式数 |
| JANE STREET GROUP, LLC | $7,462,700 | 505,603 | 0.62% | 株式数 |
| Balyasny Asset Management L.P. | $7,380,000 | 500,000 | 0.61% | プットオプション |
| LMR Partners LLP | $6,642,000 | 450,000 | 0.55% | プットオプション |
| NOMURA HOLDINGS INC | $6,273,000 | 425,000 | 0.52% | コールオプション |
| DIADEMA PARTNERS LP | $5,904,000 | 400,000 | 0.49% | コールオプション |
| Swiss National Bank | $5,319,504 | 360,400 | 0.44% | 株式数 |
| XTX Topco Ltd | $5,300,168 | 359,090 | 0.44% | 株式数 |
| Ikarian Capital, LLC | $5,235,372 | 354,700 | 0.44% | プットオプション |
| CITIGROUP INC | $4,659,717 | 315,699 | 0.39% | 株式数 |
| RENAISSANCE TECHNOLOGIES LLC | $4,580,973 | 310,364 | 0.38% | 株式数 |
| DAGCO, INC. | $4,351,740 | 1,028,780 | 0.36% | 株式数 |
| Everhart Financial Group, Inc. | $4,251,146 | 288,018 | 0.35% | 株式数 |
| Rafferty Asset Management, LLC | $3,540,806 | 239,892 | 0.29% | 株式数 |
| RHUMBLINE ADVISERS | $3,400,726 | 230,402 | 0.28% | 株式数 |
| Walleye Capital LLC | $3,377,088 | 228,800 | 0.28% | プットオプション |
| GOLDMAN SACHS GROUP INC | $3,125,991 | 211,788 | 0.26% | 株式数 |
| TUDOR INVESTMENT CORP ET AL | $3,087,792 | 209,200 | 0.26% | プットオプション |
| WELLINGTON MANAGEMENT GROUP LLP | $2,992,738 | 202,760 | 0.25% | 株式数 |
| BOOTHBAY FUND MANAGEMENT, LLC | $2,982,996 | 202,100 | 0.25% | プットオプション |
| Jefferies Financial Group Inc. | $2,958,775 | 200,459 | 0.25% | 株式数 |
| Jefferies Financial Group Inc. | $2,953,476 | 200,100 | 0.25% | プットオプション |
| Mariner, LLC | $2,925,609 | 198,212 | 0.24% | 株式数 |
| MILLENNIUM MANAGEMENT LLC | $2,895,912 | 196,200 | 0.24% | コールオプション |
| Bank of New York Mellon Corp | $2,801,212 | 189,784 | 0.23% | 株式数 |
| ALPS ADVISORS INC | $2,776,459 | 188,107 | 0.23% | 株式数 |
| JANE STREET GROUP, LLC | $2,405,880 | 163,000 | 0.20% | プットオプション |
| LPL Financial LLC | $2,297,586 | 155,663 | 0.19% | 株式数 |
| SIMPLEX TRADING, LLC | $2,274,501 | 154,099 | 0.19% | 株式数 |
| BlackRock, Inc. | $2,222,708 | 150,590 | 0.19% | 株式数 |
| WELLS FARGO & COMPANY/MN | $2,208,775 | 149,646 | 0.18% | 株式数 |
| Vontobel Holding Ltd. | $2,166,207 | 146,762 | 0.18% | 株式数 |
| TUDOR INVESTMENT CORP ET AL | $2,069,352 | 140,200 | 0.17% | コールオプション |
| Vanguard Global Advisers, LLC | $1,918,874 | 130,005 | 0.16% | 株式数 |
| VANGUARD ASSET MANAGEMENT, Ltd | $1,859,598 | 125,989 | 0.15% | 株式数 |
| Caption Management, LLC | $1,845,000 | 125,000 | 0.15% | プットオプション |
| PROFUND ADVISORS LLC | $1,780,159 | 120,607 | 0.15% | 株式数 |
| MetLife Investment Management, LLC | $1,624,810 | 110,082 | 0.14% | 株式数 |
| Daiwa Securities Group Inc. | $1,589,652 | 107,700 | 0.13% | プットオプション |
| Daiwa Securities Group Inc. | $1,512,900 | 102,500 | 0.13% | 株式数 |
| DIADEMA PARTNERS LP | $1,476,000 | 100,000 | 0.12% | プットオプション |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | $1,467,144 | 99,400 | 0.12% | 株式数 |
| STATE OF WISCONSIN INVESTMENT BOARD | $1,405,300 | 95,210 | 0.12% | 株式数 |
| Harvest Investment Services, LLC | $1,394,554 | 94,482 | 0.12% | 株式数 |
| ORBIMED ADVISORS LLC | $1,365,300 | 92,500 | 0.11% | プットオプション |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $1,229,582 | 83,305 | 0.10% | 株式数 |
| Invesco Ltd. | $1,104,816 | 74,852 | 0.09% | 株式数 |
| Gotham Asset Management, LLC | $1,097,317 | 74,344 | 0.09% | 株式数 |
| FULCRUM WEALTH ADVISORS, LLC | $1,081,214 | 73,253 | 0.09% | 株式数 |
| ALLIANCEBERNSTEIN L.P. | $998,534 | 236,060 | 0.08% | 株式数 |
| NEW YORK STATE COMMON RETIREMENT FUND | $978,588 | 66,300 | 0.08% | 株式数 |
| Verition Fund Management LLC | $916,596 | 62,100 | 0.08% | プットオプション |
| OSAIC HOLDINGS, INC. | $889,776 | 60,284 | 0.07% | 株式数 |
| FIFTH THIRD BANCORP | $888,404 | 60,190 | 0.07% | 株式数 |
| State of New Jersey Common Pension Fund D | $857,069 | 58,067 | 0.07% | 株式数 |
| Verition Fund Management LLC | $832,464 | 56,400 | 0.07% | コールオプション |
| Police & Firemen's Retirement System of New Jersey | $821,630 | 55,666 | 0.07% | 株式数 |
| ARIZONA STATE RETIREMENT SYSTEM | $731,388 | 49,552 | 0.06% | 株式数 |
| Caption Management, LLC | $728,745 | 49,373 | 0.06% | 株式数 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $722,310 | 48,937 | 0.06% | 株式数 |
| Russell Investments Group, Ltd. | $704,494 | 47,730 | 0.06% | 株式数 |
| SIG BROKERAGE, LP | $689,292 | 46,700 | 0.06% | コールオプション |
| Vanguard Investments Australia, Ltd. | $684,643 | 46,385 | 0.06% | 株式数 |
| COMMONWEALTH EQUITY SERVICES, LLC | $665,481 | 45,087 | 0.06% | 株式数 |
| INSTRUMENTAL WEALTH, LLC | $662,931 | 44,914 | 0.06% | 株式数 |
| Persistent Asset Partners Ltd | $655,647 | 758 | 0.05% | コールオプション |
| Virtus Investment Advisers, LLC | $616,791 | 41,788 | 0.05% | 株式数 |
| Accurate Wealth Management, LLC | $614,707 | 47,462 | 0.05% | 株式数 |
| AXXCESS WEALTH MANAGEMENT, LLC | $610,665 | 41,373 | 0.05% | 株式数 |
| KLP KAPITALFORVALTNING AS | $600,732 | 40,700 | 0.05% | 株式数 |
| SJS Investment Consulting Inc. | $590,400 | 40,000 | 0.05% | 株式数 |
| Wealthfront Advisers LLC | $587,773 | 39,822 | 0.05% | 株式数 |
| Quantinno Capital Management LP | $546,651 | 37,036 | 0.05% | 株式数 |
| Visionary Horizons, LLC | $531,360 | 36,000 | 0.04% | 株式数 |
| Kestra Advisory Services, LLC | $516,305 | 34,980 | 0.04% | 株式数 |
| NORTHSTAR ASSET MANAGEMENT Co | $509,400 | 45,000 | 0.04% | 株式数 |
企業インサイダー 42 人のインサイダー · 17人の役員 · 9人の取締役
| インサイダー | 役職 | 最終アクティビティ | 保有株式数 | 12ヶ月購入 | 12ヶ月売却 | 12ヶ月純額 |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 2026年6月16日 A | 1,759,183 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 2011年3月15日 A | 92,994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 2026年1月7日 A | 554,327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 2018年4月20日 A | — | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 2011年4月13日 A | 379,294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 2009年1月15日 A | — | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 2026年1月7日 A | 557,805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 2024年1月22日 A | 40,918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 2024年1月22日 A | 117,225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 2019年3月14日 A | — | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 2018年3月13日 A | — | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 2011年3月15日 A | 14,065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 2011年3月15日 A | 41,083 | 0 | 0 | $0 |
| Anastasia Khvorova | Chief Science Officer | 2011年3月15日 A | 60,559 | 0 | 0 | $0 |
| Pamela Pavco | VP of Pharmaceutical Devlpmt | 2011年3月15日 A | 44,940 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 2010年4月15日 A | 5,750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 2010年3月31日 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | 取締役 | 2026年1月7日 A | 154,400 | 1 | 0 | $100,806 |
| John Varian | 取締役 | 2026年1月7日 A | 72,900 | 0 | 0 | $0 |
| Jane Wasman | 取締役 | 2026年1月7日 A | 92,900 | 0 | 0 | $0 |
| David A Scheinberg | 取締役 | 2026年1月7日 A | 73,082 | 0 | 0 | $0 |
| Robert L Van Nostrand | 取締役 | 2026年1月7日 A | 82,900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | 取締役 | 2019年3月14日 A | — | 0 | 0 | $0 |
| Fabio Lopez | 取締役 | 2018年6月12日 A | — | 0 | 0 | $0 |
| Irving M. Einhorn | — | 2017年10月10日 A | 34,690 | 0 | 0 | $0 |
| William Ashton | — | 2017年10月10日 A | 38,154 | 0 | 0 | $0 |
| Richard Chin | — | 2017年10月10日 A | 31,339 | 0 | 0 | $0 |
| Rudolph Nisi | — | 2017年10月10日 A | 42,918 | 0 | 0 | $0 |
| Sanford Hillsberg | — | 2017年10月10日 A | 56,950 | 0 | 0 | $0 |
| Mary Ann Gray | — | 2017年10月10日 A | 39,167 | 0 | 0 | $0 |
| Stephen S Galliker | — | 2017年10月10日 A | 36,039 | 0 | 0 | $0 |
| Thomas J Knapp | — | 2017年2月6日 A | — | 0 | 0 | $0 |
| Bijan Nejadnik | — | 2017年1月17日 A | — | 0 | 0 | $0 |
| Ryan Dunlap | — | 2016年6月1日 M | 18,702 | 0 | 0 | $0 |
| Mark W. Schwartz | — | 2015年12月18日 A | 415,972 | 0 | 0 | $0 |
| Steven A Kriegsman | — | 2015年6月19日 A | 5,000 | 0 | 0 | $0 |
| Margaret Kivinski | — | 2015年1月16日 A | — | 0 | 0 | $0 |
| Brian L Hamilton | — | 2014年6月30日 J | 2,461 | 0 | 0 | $0 |
| Mark J Ahn | — | 2014年6月30日 A | 116,225 | 0 | 0 | $0 |
| Rosemary Mazanet | — | 2013年1月29日 A | — | 0 | 0 | $0 |
| CYTRX CORP | — | 2010年12月29日 S | 0 | 0 | 0 | $0 |
| Tod Woolf | — | 2009年1月15日 A | — | 0 | 0 | $0 |
SECフォーム3/4/5提出書類からのインサイダー；純額＝公開市場のP/Sのみ
アクティビストおよび5%超のオーナー 2保有
SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図（アクティビストの保有、取締役会キャンペーン、M&A）を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。
| 提出者 | 提出済み | 保有 | ステータス | 目的 | 提出書類 |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 提出書類 | 2018年10月10日 | — | 初回提出 | — | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 2018年1月8日 | — | 初回提出 | M&A / 売却 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF保有状況 29のETFが保有
ウェイトは直接株式保有（N-PORT）のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。
| ファンド | ウェイト | 単位 | 時点 | ソース |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0.77% | 288,499 SH | 2026年8月8日 | 日次 |
| IWC · iShares Trust | 0.50% | 640,415 SH | 2026年8月8日 | 日次 |
| LABU · Direxion Shares ETF Trust | 0.26% | 268,465 NS | 2026年4月30日 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.23% | 316,525 SH | 2026年8月8日 | 日次 |
| ICOP · iShares Trust | 0.22% | 126,361 SH | 2026年8月8日 | 日次 |
| CANC · Tema ETF Trust | 0.22% | 40,702 NS | 2026年5月31日 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.16% | 202,339 SH | 2026年8月8日 | 日次 |
| IWO · iShares Trust | 0.14% | 1,712,069 SH | 2026年8月8日 | 日次 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.08% | 1,086,285 SH | 2026年8月8日 | 日次 |
| IWM · iShares Trust | 0.07% | 4,828,431 SH | 2026年8月8日 | 日次 |
| ISCG · iShares Trust | 0.07% | 57,511 SH | 2026年8月8日 | 日次 |
| GSSC · Goldman Sachs ETF Trust | 0.05% | 51,293 NS | 2026年5月31日 | N-PORT |
| PICK · iShares, Inc. | 0.04% | 122,564 SH | 2026年8月8日 | 日次 |
| ITWO · ProShares Trust | 0.04% | 8,088 NS | 2026年5月31日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.04% | 540,244 SH | 2026年8月8日 | 日次 |
| ISCF · iShares Trust | 0.04% | 30,200 SH | 2026年8月8日 | 日次 |
| ISCB · iShares Trust | 0.03% | 8,283 SH | 2026年8月8日 | 日次 |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 2,134,285 SH | 2026年8月8日 | 日次 |
| WSML · iShares Trust | 0.03% | 16,889 SH | 2026年8月8日 | 日次 |
| RSSL · Global X Funds | 0.03% | 74,459 NS | 2026年4月30日 | N-PORT |
| UWM · ProShares Trust | 0.02% | 6,326 NS | 2026年5月31日 | N-PORT |
| URTY · ProShares Trust | 0.02% | 6,397 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.01% | 161 NS | 2026年5月31日 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 64,480 NS | 2026年5月31日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.00% | 3,554 NS | 2026年5月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 273,812 SH | 2026年8月8日 | 日次 |
| IWV · iShares Trust | 0.00% | 43,929 SH | 2026年8月8日 | 日次 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 5,908,560 SH | 2026年8月8日 | 日次 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 15,706 SH | 2026年8月8日 | 日次 |